Introduction: Achieving ambitious targets for the identification and successful treatment of patients with tuberculosis (TB) requires consideration of the likely impact of potential interventions. Cost Effectiveness Analysis (CEA) and Benefit Cost Analysis (BCA) are two approaches to economic evaluation that assess the costs and effects of competing alternatives, however the differing theoretical basis and methodological approach to CEA and BCA is likely to result in alternative analytical outputs and potentially different policy interpretations.
Introduction
The aim of this case study is to assess the expected impact of investing in various tuberculosis (TB) control interventions in the South African context using a benefit cost-analysis (BCA) approach. The analysis is informed by the Guidelines for BCA project (1) and converts outputs of a cost effectiveness analysis (CEA). This approach will enable comparison of CEA and BCA analysis of the same interventions in the same context and is intended to assist in further refinement of methodological guidance provided in the Guidelines for BCA project and the International Decision Support Initiative (IDSI) Reference Case for economic evaluation (2) .
Policy context
TB remains a significant policy priority globally. In 2016, 1.7 million people died as a result of TB including 0.4 million deaths among people with human immunodeficiency virus (HIV). TB is the leading cause of death in South Africa with a mortality rate of 181 per 100,000 in HIV+ patients and 41 per 100,000 in patient without HIV (3) . Since 1990, globally there has been a 47% decline in the TB mortality rate and the HIV-related TB deaths have reduced by 32% since 2005. (3) Between 2015 and 2030, the Sustainable Development Goals (SDG) aim to reduce the global number of TB deaths by 90%, reduce the TB incidence rate by 80%, and eliminate catastrophic costs on households as a result of TB. Pillar 1 of the World Health Organisation's (WHO) End TB strategy focusses on integrated, patient-centred TB care and prevention, and includes "early diagnosis of TB including universal drug-susceptibility testing and systematic screening of contacts and high-risk groups" and "collaborative TB/HIV activities"(4). South Africa's National Strategic Plan (NSP) for HIV, TB and STIs 2017-2022 (NSP) outlines the roadmap for a national response to HIV, TB and Sexually transmitted infections (STIs), recognising the need for a comprehensive and integrated response (5) . Aligned to the SDG targets, the NSP aims to reduce national TB incidence from 450,000 to less than 315,000 per year by 2022, including diagnosis of 90% of people with TB, treating 100% of those diagnosed and achieving successful treatment for 90% of patients with drug-susceptible TB.
Goal 2 of the NSP aims to reduce morbidity and mortality by providing treatment, care and adherence support for all, specifying increased need for screening and testing programmes to appropriately identify patients in order to initiate treatment. The TB Targets project assessed the impact of interventions aimed at reaching the End TB strategy target and demonstrated that a range of interventions would be required across the spectrum TB care (6) . Central to achieving the ambitious targets for reducing TB incidence and mortality involves optimal use of available resources, and developing innovative ways of managing the identification, diagnosis and treatment of TB tailored to local country context and constraints. The TB Targets analysis found that Intensive Case Finding (ICF) was the single most effective intervention for reaching NSP targets, but was also the most expensive, demonstrating the need for increased resource allocation and further research on the optimal approach to implementation of case finding strategies in the South African context. (7) After receiving conditional programmatic recommendation from WHO in 2010, a new diagnostic test Xpert MTB/RIF was rolled out in South Africa in 2012, marking a milestone development in the identification of patients with TB (8) . Compared to existing diagnostic regimens, multiple economic evaluations predicted that Xpert MTB/RIF would be cost effective in a range of settings, including South Africa (9) . However, a cost-effectiveness analysis investigated the effect of Xpert utilising data from a pragmatic cluster randomised trial (XTEND study) conducted during roll-out of the new technology in South Africa, and found that Xpert was highly unlikely to have improved the costeffectiveness of TB diagnosis at a range of cost-effectiveness thresholds during its early stage of rollout (9) . This finding demonstrated the need to explore implementation constraints and fully explore the relative value of different options for identification of persons needing screening and diagnostics for TB, leading to the analysis used for this case study.
Approach to the case study
The original CEA assessing the TB control interventions (Bozzani et al, in press) was developed combining impact estimates generated using the TIME epidemiological transmission model with cost estimates from the literature and micro-costing of TB control at sites across South Africa, to estimate the cost-effectiveness of specific interventions detailed in Figure 1 The TIME model (a deterministic epidemiological model) was developed by the London School of Hygiene and Tropical Medicine in collaboration with Avenir Health as a user-friendly tool to predict the impact of interventions along the TB transmission, diagnosis and treatment pathway in highburden settings. The cost-effectiveness analysis that this case study is based on assessed specific interventions related to screening and diagnosis, and utilised the TIME model to estimate likely outcomes.
In completing the case study, the recommended BCA methodological approaches were applied to the original analysis where feasible, and no additional primary analysis or data collection was conducted.
In addition to applying the methodological specifications developed under the Guidelines for BenefitCost Analysis project, the case study attempts to conform with recommendations of the linked initiatives the IDSI Reference Case (2), and guidance from the Global Health Cost Consortium Project (10).
Policy options
The NSP for TB in South Africa requires a substantial and rapid scale-up of approaches to identify patients with TB and effectively initiate them on the right treatment. There are a range of policy options that can be applied individually or in combination to improve TB patient identification, and by comparing the expected costs and benefits associated with each option, the optimal combination can be identified. The analysis compares ten mutually exclusive interventions (status quo plus six unique interventions and three intervention combinations) for improving TB control as shown in Figure 1 and Figure 2 below. The potential interventions in Figure 1 were identified in discussion with policy makers and represent the realistic and immediate policy options.
The current measure to identify patients to initiate the TB diagnostic pathway include 1) passive screening, which relies on patients actively seeking care, 2) cough triage, which includes a simple question to patients about history of coughing symptoms, and 3) a structured questionnaire with specific questions related to patient symptoms and clinical history developed by the World Health Association (WHO symptoms screening tool). Currently 40% of patients who are HIV positive are screened for TB symptoms using the WHO symptoms screening tool, and staff at Primary Health Clinics (PHC) passively screen all patients for TB. The available options to scale up TB control involve six potential interventions, each of which have associated costs and expected benefits. The options include increasing Xpert coverage from 80% to 100%; increasing microscopy follow-up of those who have a negative Xpert result from 14% to 90%; triaging all HIV+ and 90% of all PHC patients for cough assessment; and performing WHO symptoms screening in 100% of HIV+ patients and 90% of all PHC patients, respectively. In addition, a further three combinations were assessed that consisted of the Xpert interventions (100% Xpert coverage and 90% follow-up of negative results), the Xpert interventions combined with cough triage in 90% of all PHC patients, or Xpert interventions combined with WHO symptoms screening in 90% of all PHC patients. The impact of the interventions strategies was estimated utilising the TIME model, with costs and effects modelled at specific stages in the causal pathway of TB as shown in Figure 2 . 
Perspective
The CEA was conducted from the perspective of the health service provider, which in this instance is the South African government. In the South African public health sector, TB care is provided free of charge to patients at the point of use. This means that the government finances all direct health systems costs and patients are not required to make any financial contribution to the direct health services costs associated with accessing TB treatment beyond general government taxation.
In terms of indirect and non-health systems costs, a costing analysis involving TB patients in South Africa found 69% of those who were confirmed to have TB reported no income, and a further 5% accessed government cash transfers as their main source of income (receipt of which would not be impacted by disease). This indicates that patients in South Africa suffer relatively low levels of income loss from TB due to the context of high unemployment rates. In addition, transport costs were relatively low as many patients in the study sample were able to access facilities within walking distance or a short journey from their home (11). The low transport costs may not be representative of the total population in South Africa, as some patients in rural communities may need to travel substantial distances to access care. Further research is required to fully assess the indirect costs faced by this patient population in the South African context. This analysis will present costs from a government healthcare provider perspective, and the welfare gains to individuals will be estimated according to methodological specifications in the BCA project. Additional sensitivity analysis, including costs incurred by 3 rd parties (such as carers assisting patients to access health services), will be included in the analysis. Benefits incurred by patients in terms of mortality and morbidity reduction will be incorporated and valued according to recommendations of the BCA reference case.
Baseline Conditions
The baseline comparators are detailed in Figure 1 and consist of Xpert coverage for 80% of cases, limited follow-up (14%) of those that receive negative Xpert result, WHO symptoms screening for less than half of patients with HIV, and passive screening of patients in PHCs. An important aspect of this analysis is that it is not assessing whether or not to introduce a new individual technology, but assessing the costs and benefits of investing additional resources in order to achieve target levels of TB patient identification. Therefore, the current baseline comparator is the existing screening algorithm, with associated levels of staffing, equipment and technologies at South African health facilities.
As the interventions represent up-scaling of existing interventions, it is not predicted that there would be major societal shifts or structural changes to the economy as a result of implementing the interventions, beyond of course the potential significant mortality and morbidity benefits of improved management of TB.
The IDSI RC recommended that, while current practice should be used in base case analysis, additional analysis should be conducted using best supportive, non-interventional care as a comparator where appropriate to the decision problem. This case study does not incorporate a non-interventional comparator as the current policy decision that this analysis seeks to answer is restricted to utilising existing diagnostic technologies and processes available in South Africa. In addition, applying a noninterventional ("do-nothing") comparator for diagnostic interventions would require substantial assumptions about the down-stream management of TB that may limit the usefulness of any findings of such an analysis.
Expected impact
The expected impacts of the different policy options are differing levels of resource use, largely because of staffing requirements to carry out the scaled-up interventions, and a corresponding improvement in TB patient identification with downstream impact on TB care and ultimately reduced TB-related mortality and morbidity. The use of more intensive screening interventions incurs more nurse time, and improved sensitivity generates more diagnostic tests downstream with associated costs but improved patient outcomes. A central assumption in predicting impact is related to the causal pathway from diagnosis to appropriate treatment, and then treatment to patient outcomes. In this analysis, common assumptions about treatment outcomes are applied consistently to all interventions and are based on outputs from the TIME epidemiological model. The major impact areas modelled include numbers of patients screened for TB using the passive and WHO approaches, the number of smear microscopy and Xpert diagnostic tests completed, the number of patients initiated on first-line and multi-drug resistant (MDR) regimens, and reduction in the number of total personyears of untreated active disease. Table 1 shows the expected impact of each of the interventions under consideration on health system outcomes (in '000s) over the 20-year period from 2015-2035 compared to the status quo. Importantly, all interventions are expected to substantially reduce the number of person-years of untreated active disease -a key indicator for reduction in TB transmission. Intervention 7 (100% screening of all patients who are HIV+) is expected to result in more than 447 million patient screening events using the structured WHO survey, with a resultant reduction in number of patients passively screened and increase in diagnostic tests performed and patients initiated on treatment. Intervention 10 (increased Xpert coverage and follow-up, and symptoms screening of 90% of all PHC attendees) is expected to yield the greatest reduction in untreated active disease, more than 833 million additional screens and 181 million additional Xpert diagnostic tests over the 20-year period. 
Costs
This case study adopts the recommendations of the BCA RC guidance in determining costs and benefits. Estimates of net costs of the interventions followed guidance of the Global Health Costing Consortium Reference Case (10) and involved combining the output of the TIME epidemiological model with costing parameters derived from local South African data.
The cost of key elements within the care pathway were estimated using a micro costing approach. For example, costs of drug regimens were estimated by calculating total number of tablets/injections required over the course of treatment multiplied by their unit cost, and screening costs involved the unit cost of the test per patient plus health professional time. Compared to the status quo scenario, the cost-impact of key elements of the management pathway for the period 2015-2035 (discounted at an annual rate of 3%) are detailed in Table 2 and Table 3 . The Xpert diagnostic test is a driver of cost under most intervention scenarios. Xpert costs are estimated in excess of $4 billion over the 20-year period, with an additional $71 million for 1st line and MDR TB treatment costs. Intervention 5 (cough triage for 100% of HIV+ patients) is expected to result in savings in most elements of care due to a reduction in TB cases over time.
Benefits
In line with the recommendations of the BCA Reference Case guidance, this case study adopts a "benefits transfer" approach to estimate the monetary value of mortality and morbidity risk reduction (12) (13). A benefits transfer approach applies the benefit valuation observed in one county or jurisdiction to another with relevant adjustments, and was selected as a literature search did not identify literature of sufficient quality to estimate the Value of Statistical Life (VSL) in South Africa directly. Equation 1 shows the approach to calculating the values used in the benefits transfer, where the VSLtarget is the estimated VSL in South Africa, VSLbase is the value in the originating country, and income is the GNI per capita adjusted for purchasing power parity. 
Equation 2
The values to estimate the VSL for the South African target population used in this case study are informed by the BCA reference case guidance (12) , and include three approaches for parameters in Equation 2 above. The VSL was adjusted for expected economic growth in future years by applying equation 1 above. Assuming an elasticity of 1, the VSL in any year (VSLtarget) will be proportional to the per capita Income in the target year divided by per capita Income in the base year multiplied by the VSL used in the base year. The International Monetary Fund average projected per capita GDP growth to 2023 for South Africa (2.52%) (14) was assumed to represent a reasonable estimation of the annual expected change in per capita income year to year and was used to estimate annual VSL growth to 2035. 
Value of mortality risk reduction
The projected deaths avoided as a result of the different interventions over the period 2015-2035 (undiscounted) are shown in Table 5 . All interventions are expected to avoid a substantial number of deaths relative to the status quo, with intervention 10 expected to yield the largest reduction in mortality at over 73,000 deaths avoided over the 20-year period. The valuation of the mortality risk reduction is also shown in Table 5 , using VSL detailed in Table 4 and discounted at an annual rate of 3%. 
Value of morbidity risk reduction
The approach to valuing morbidity follows the BCA Reference Case guidance (13). Ideally the approach to estimating the VSLY would be based on locally-derived and high-quality willingness to pay estimates for the target population (i.e. patients with TB in South Africa), or a valuation function. However, these are currently not available so as a proxy, a constant Value of Statistical Life Year (VSLY) was derived from a monetised disability-adjusted life year (DALY). The proposed VSLY estimates are detailed in Table 6 and are derived from the different approaches to estimate the VSL in Table 4 and divided by 32.83 years (the mean expected numbers of years of life remaining for the average patient who was 15+ years old in the target population). This approach relies on strong assumptions as detailed in the BCA RC guidance, including that 1) the VSLY is constant, 2) the VSLY as calculated is equivalent to a DALY, and 3) the value per DALY is constant. Using established disability weights from the literature for the relevant health states (with and without active TB in combination with different HIV states) (15), the total estimated morbidity reduction associated with each intervention over the period 2015-2035 is detailed in Table 7 and discounted at 3% annually. Monetised benefit of the morbidity reduction is calculated by multiplying the morbidityrelated DALYs averted by the VSLY values detailed in Table 6 , with and without 3 rd -party costs added. Table 7 shows that Intervention 10 is expected to avert the highest number of DALYs averted (58, 609) at a monetised value of Int$3.6 billion over the 20-year period using approach 1 and incorporating 3 rd party costs.
The BCA RC guidance notes that VSLY estimates are assumed to incorporate non-health systems costs incurred by the individual, and so these costs are not added to the VSLY estimates. There is some uncertainty as to whether it is appropriate to add 3 rd -party costs (e.g. those included by household or family members). An analysis of the economic costs of TB in South Africa (11) found the mean guardian/carer costs per diagnostic and treatment episode to be US$114.10. Assuming this cost would be incurred by 3 rd parties for all patient initiating 1 st line or MDR treatment under the different interventions, the impact of this 3 rd -party cost on the value of morbidly reduction (discounted at 3% annually) is also incorporated in Table 7 for comparison. Interventions that will result in a net reduction in initiations of TB treatments (e.g. Intervention 2), the inclusion of 3 rd party costs increase the net morbidity related value, whereas interventions that increase the numbers initiating treatment (e.g. intervention 6) result in decreased value as additional treatment initiations result in higher 3 rd party costs. In this scenario, the inclusion of 3 rd -party costs represents a small proportion of the benefit compared to VSLY, with the mean increase in valuation across the interventions ranging from 0.98% (when using Approach 1) to 2.05% (when using Approach 3). 
Net benefits
The net benefits calculation followed the BCA RC guidance by subtracting total costs from total monetized benefits to estimate net benefits as detailed in Table 8 and Table 9 . All interventions are estimated to result in positive net benefits compared to status quo. Regardless of approach to estimate the VSL, intervention 10 (improved Xpert access and follow up, WHO symptoms screening in 90% of PHC patients) appears to offer the greatest net benefit over the 20-year period, at between Int$135 billion (Approach 1) and $58.4 billion (Approach 3). Intervention 5 (cough triage in all HIV+ patients) represented the lowest net benefits, ranging from Int$4.9 billion (Approach 1) to Int$3.0 billion (Approach 3). 
Return on Investment
The BCA RC guidance notes that return on investment (ROI) calculations may be presented, however results should be interpreted with caution as ROI is influenced by the allocation of costs as either inputs or outputs (1).
ROI calculations for the interventions are shown in Table 10 . Intervention 5 was estimated to be cost saving to the health system (i.e. had negative input costs) and so the ROI cannot be calculated but is represented in the table as greater than 100 to give an indication of relative favourable returns. Further analysis of intervention 5 would enable a more accurate estimation of the ROI. Intervention 10, which was estimated to have the greatest net benefits of all the interventions, has a relatively low estimated ROI, reflecting the large costs associated with implementation. 
Distribution of effects
Incidence of TB is heavily influenced by income and socioeconomic status. Despite significant reductions in the rate of poverty 1 from 1996, the poverty rate in South Africa has increased to 18.9% in 2015 from 16.9% in 2008. As TB is both a cause and effect of poverty, the distributional of the social benefits and costs associated with the TB control interventions across the South African population is highly relevant to the policy recommendation (13).
Even though TB care in South Africa is largely free at the point of use, patients experience direct and indirect costs associated with the disease and in accessing TB diagnosis and treatment. An extended cost-effectiveness analysis that utilised the same epidemiological model (TIME) as this case study estimated the impact of expanded TB services on households in South Africa and India (16) . The study found that in the South African base case scenario, 1.1 to 1.2 million households would experience catastrophic costs related to TB over the period 2015-2030, with 80% of catastrophic costs experienced in the bottom quintile, and zero households in the top quintile experiencing catastrophic costs. Expanded access to TB services in South Africa was estimated to reduce TB-related catastrophic costs by 5-20%, with the majority of benefits accruing to poorest households.
All interventions within this case study reduce the amount of untreated active TB and avert significant morbidity and mortality. This case study was unable to make accurate quantitative estimations of the distributional impacts of the different interventions as although the socioeconomic status of patients passively screen for TB is known, it is uncertain precisely how the benefits of more intensified case finding and screening will be distributed. It is expected however that the intervention effects will mainly be experienced by poor and impoverished households and that interventions with larger reductions in TB-associated morbidity and mortality are likely to have a greater impact on households in lower-income quintiles. As TB interventions in South Africa are largely delivered in the public sector and are free at the point of use to patients, the cost of the interventions falls on government revenue, through a broadly progressive taxation system.
Discussion
This case study aimed to demonstrate the methodological specifications of the BCA RC guidance and was applied to an existing cost-effectiveness analysis of 10 interventions to improve access and diagnosis of TB in the South African setting.
The interventions all demonstrated positive net benefits and although this case study provides a useful estimate of the different interventions using a benefits transfer approach to the valuation of statistical lives and statistical life-years, further analysis would be required to establish a policy recommendation in the South African setting. The CEA results found that Intervention 5 (cough triage in 100% of HIV+ patients) is expected to result in net health service savings and generate positive health outcomes, and under a CEA framework would be described as dominating the status quo (Intervention 1), and would likely receive a positive policy recommendation even under scenarios where the costeffectiveness threshold is either extremely low or unknown. Interventions 3, 4, 6, 7 and 8 are either strongly or extendedly dominated, indicating that for any given cost effectiveness threshold, an alternative intervention exists that represents a more favourable use of resources 2 . Intervention 10 (100% Xpert coverage, 90% follow-up of Xpert negatives and WHO symptoms screen in 90% of all PHC patients) is expected to have the highest Incremental Cost Effectiveness Ratio (ICER). It represents a potentially viable policy option but the ICER for intervention 10 is likely to be higher than a recent cross-country analysis of cost-per DALY ranges in number of countries that estimated the cost-per DALY threshold in South Africa at between US$1,175 -US$4,714 per DALY averted (17) . Intervention 5 (cough triage in all HIV+ patients) and Intervention 9 (100% Xpert coverage and follow up of 90% of patients with a negative Xpert result) are also potential policy options depending on the cost effectiveness threshold used in the South African setting to guide health system investments.
Under the BCA framework, intervention 5 represents the lowest net benefit as although the costs are negative, the per patient health impact is relatively low. With net savings to the health system, Intervention 5 offers the most favourable ROI. The BCA framework indicates that Intervention 10 has the highest net benefit under all approaches to VSL calculation, but a relatively low return on investment given the high implementation costs. A decision framework for the interpretation of net benefits and ROI is not currently available to represent the South African policy perspective and health system context so this report is unable to definitively recommend Interventions as policy options beyond Intervention 5 (which is cost saving and has positive outcomes).
Contrasting the results utilising the CEA and BCA frameworks highlight the differing theoretical underpinnings of the approaches. The CEA provides a series of ICERs estimating incremental health system costs and DALYs accrued to individual patients, while the BCA case study provides monetized net benefits of the same health system costs and estimations of individual willingness to pay for mortality and morbidity risk reduction, and estimates of return on investment. Both approaches identified intervention 5 as cost saving and providing positive health effects relative to status quo. Applying a VSL of between Int$0.98 -Int$2.1 million to lives saved reduced the relative importance of small changes in input costs between interventions, resulting in the intervention with the greatest health impact yielding the greatest net benefit (Intervention 10). A more granular approach to estimating return on investment than provided in this case study would improve understanding of the relative efficiency of each intervention under the BCA framework, but the incremental approach adopted in CEA allows the ruling out of dominated interventions that was not applied in the BCA approach.
The CEA and BCA approaches in this case study reflect a judgement on whether social values imbedded in economic evaluation ought to reflect those implied by the outcome of legitimate processes (in this case a democratically-elected government setting budgets for health care) or a notion of welfare founded on individual preferences or an explicit welfare function (18) . However, a key consideration for the interpretation of the results of either the CEA or BCA is health system affordability. Simplistic decision rules to implement policies based on analytical outputs that are not linked to available funding has the potential to result in net population loss of health if more efficient interventions are pushed out to fund new investments. In the South African context, completion of ongoing work to accurately estimate the marginal productivity of the public health system will assist in interpretation of CEA results, while further consideration of the appropriate interpretation of BCA results in the context of South Africa's progress towards Universal Health Coverage is required.
The results of this case study may contribute to further understanding of the nature and relationship of the costs and benefits of the different TB control interventions and the appropriate analytical technique to demonstrate value relative or other health system priorities. Ultimately, the validity of the differing approaches rests on the requirements, understanding, and informational needs of the intended decision maker, and the realities of local perspective and context.
